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Hydrocortisone administration was 
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There are few reports on hydrocortisone administration after cardiac arrest, and those that have 
been published included few subjects. This study aimed to evaluate the effect of hydrocortisone 
administration on the outcomes of patients who experienced cardiac arrest. We investigated the 
survival discharge rates and the length of hospital stay from cardiac arrest to discharge, stratified by 
use of hydrocortisone, using a Japanese health-insurance claims dataset that covers approximately 
2% of the Japanese population. The study included the data of 2233 subjects who experienced either 
in-hospital or out-of-hospital cardiac arrest between January 2005 and May 2014. These patients were 
divided into two groups, based on the administration of hydrocortisone. We adjusted the baseline 
characteristics, medical treatment, and drug administration data of the two groups using propensity 
scores obtained via the inverse probability of treatment weighted method. The hydrocortisone group 
had a significantly higher survival discharge rate (13/61 [21.1%] vs. 240/2172 [11.0%], adjusted odds 
ratio: 4.2, 95% CI: 1.60–10.98, p = 0.004). In addition, the administration of hydrocortisone was 
independent predictor of survival to discharge (hazard ratio: 4.6, p < 0.001). The results demonstrate a 
correlation between hydrocortisone administration and the high rates of survival to discharge.
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Cardiac arrest is defined as “the cessation of cardiac mechanical activity, as confirmed by the absence of signs of 
circulation”1. Approximately 356,000 out-of-hospital cardiac arrests (OHCAs) occurred from June 2014 through 
May 2015 in the United States2. In Japan, approximately 123,000 OHCAs occurred in 2015 and, given the aging of 
Japanese society, this number is expected to increase3.
Although the prognosis after cardiac arrest has improved, the rate of surviving to hospital discharge 
remains < 30%4,5. Moreover, there is a high frequency of post-resuscitation syndrome in patients who achieve 
return of spontaneous circulation (ROSC), and the proportion of patients able to return to normal life is 
extremely low6.
Several studies have reported that administration of glucocorticoids during and after resuscitation results 
in improved prognosis for cardiac arrest patients. Mentzelopoulos et al. reported that the rate of survival to 
discharge and neurological outcomes were improved by using vasopressin-steroids-epinephrine combination 
therapy during resuscitation and hydrocortisone for post-resuscitation shock7,8. In addition, Tsai et al. reported 
that using glucocorticoids during resuscitation improves the survival discharge rate, using data from the Taiwan 
National Health Insurance Research Database (NHIRD)9.
However, few reports have demonstrated the effectiveness of hydrocortisone administration during and after 
resuscitation. Tsai et al. conducted a prospective, nonrandomized, open-label clinical trial to examine the effect 
of hydrocortisone on OHCA outcomes10. They found no significant difference between the hydrocortisone and 
non-hydrocortisone groups in terms of rates of survival to discharge. Donnino et al. reported that hydrocortisone 
administration did not contribute to the reversal of shock, to improved neurological outcomes, or to improved 
rates of survival to discharge in a randomized, double-blind trial of patients with post-resuscitation shock11. 
These studies were conducted in a restricted number of medical institutions and included 100 study subjects or 
fewer. Glucocorticoid supplementation during and after cardiopulmonary resuscitation might confer a benefit 
in terms of survival to discharge, but the overall effectiveness of hydrocortisone administration in cardiac arrest 
is inconclusive. It is, thus, necessary to examine the effectiveness of hydrocortisone administration in various 
medical facilities.
Hence, in the present study, we investigated the rate of survival to discharge among patients who experienced 
cardiac arrest and received hydrocortisone by analyzing health-insurance claims data owned by the Japan Medical 
Data Center (JMDC).
Results
Baseline characteristics of patients. Of the 2233 patients included in this study, 61 (2.7%) were treated 
with hydrocortisone and 2172 (97.3%) were not. The baseline characteristics of both groups are shown in Table 1. 
Significant differences were observed between the hydrocortisone and non-hydrocortisone groups, respec-
tively, in terms of the proportion of patients who achieved ROSC (25% vs. 8%, p < 0.001); the proportion with 
chronic lung disease (46% vs. 26%, p < 0.001) or cancer (57% vs. 39%, p = 0.003); the proportion of patients who 
received vasopressin (8% vs. 1%, p < 0.001), methylprednisolone (26% vs. 4%, p < 0.001), dopamine (64% vs. 
22%, p < 0.001), noradrenaline (norepinephrine) (44% vs. 14%, p < 0.001), and lidocaine (20% vs. 6%, p < 0.001); 
the mean dosage of adrenalin (epinephrine) administered (5.63 mg vs. 2.26 mg, p < 0.001); tracheal intubation 
(51% vs. 33%, p = 0.004); artificial respiration (70% vs. 43%, p < 0.001); and hypothermia therapy (7% vs. 1%, 
p = 0.011). The groups were comparable in terms of prevalence of comorbidities. More medicines and treatments 
related to resuscitation were used in the hydrocortisone group than were used in the non-hydrocortisone group. 
The rate of survival to discharge was 21% (n = 13) in the hydrocortisone group and 11% (n = 240) in the non-hy-
drocortisone group.
Comparing rates of survival to discharge between the two groups. We performed a retrospective 
analysis of statistical power using the number of study subjects (hydrocortisone group, n = 61 and 
non-hydrocortisone group, n = 2172) and the incidence of outcomes (hydrocortisone group, 21% and 
non-hydrocortisone group, 11%) by setting the α error to 0.05: The study’s statistical power was calculated to 
be 63%12. The crude odds ratio (OR) of survival to discharge was 2.2 (95% confidence interval [CI]: 1.12–3.97, 
p = 0.015) in the hydrocortisone relative to the non-hydrocortisone group. After adjusting for baseline charac-
teristics using the inverse probability of treatment weighting (IPTW) method (Table 2), the adjusted OR was 4.2 
(95% CI: 1.60–10.98, p = 0.004) (Table 3). In addition, we used the IPTW method to analyze the data of the 1817 
cases whose dates of hydrocortisone administration and cardiac arrest we were able to determine. The hydrocor-
tisone group tended to have a higher rate of survival to discharge than the non-hydrocortisone group (22% [10/46 
cases] vs. 12% [214/1771 cases], respectively), but not significantly so (OR: 3.43, 95% CI: 0.88–13.44, p = 0.077). 
Next, we extracted a 1:1 matched cohort using the propensity score matching method (Table 2): 48 cases were 
matched. Although the rate of survival to discharge tended to be higher in the hydrocortisone group (OR: 2.8, 
95% CI: 0.88–8.64, p = 0.083), there was no statistically significant difference (Table 3).
Length of hospital stay. The median length of hospital stay from the time of cardiac arrest of hydrocorti-
sone group and non-hydrocortisone group were 15 days (interquartile range: 0–47.5) and 31 days (interquartile 
range: 3–122), respectively. In the Cox proportional hazard regression analysis, adjusted using IPTW, age (haz-
ard ratio: 1.02, 95% CI: 1.01–1.03, p = 0.003) and administration of hydrocortisone (hazard ratio: 4.61, 95% CI: 
2.18–9.72, p < 0.001) were associated with a higher rate of survival to discharge (Fig. 1, Table 4).
Discussion
The purpose of the present study was to assess the effect of hydrocortisone on the outcome of patients with 
cardiac arrest; we demonstrated an association between hydrocortisone administration and high rates of sur-
vival to discharge. Although the effectiveness of glucocorticoid administration during and after resuscitation has 
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been reported7–9, the effectiveness of hydrocortisone administration has been inconclusive. Tsai et al. investigated 
whether outcomes improved when hydrocortisone 100 mg was administered during the resuscitation of OHCA 
patients10. They found that ROSC rates improved, but that there was no significant difference in survival discharge 
rate. Donnino et al. conducted a randomized, double-blind, placebo-controlled study11. Either hydrocortisone 
100 mg or placebo was administered to study subjects for seven days or every eight hours until shock reversal. The 
result indicated that there was no significant difference in shock reversal or survival discharge rates.
In the present study, unlike previous reports, hydrocortisone administration after cardiac arrest was associated 
with higher rates of survival to discharge. One of the differences between the present study and previous studies 
is the number of in-hospital cardiac arrest (IHCA) patients included. Indeed, the study by Tsai et al. was limited 
to OHCA patients and in the study by Donnino et al., 76% of patients had OHCA. However, the present study 
sample comprised 85% IHCA patients. Therefore, one of the major features of our research is that we included 
many patients with cancer.
In this study, the ratio of vasoactive medication use was higher in the hydrocortisone group than in the 
non-hydrocortisone group. Because hydrocortisone is known to have a vasopressor effect13, we presume that it 
was used to improve prognosis in patients who remained hypotensive despite the use of other vasopressors. In 
this study, after adjusting the balance of each factors by propensity score analysis, the odds ratios for survival to 
discharge was significantly higher in that group than in the non-hydrocortisone group.
We also conducted a comparison using the Cox proportional-hazards regression analyses for time from 
cardiac arrest to discharge: The hydrocortisone group was more likely to discharge in early. In the study by 
Donnino et al., there was no significant difference in the time to shock reversal according to hydrocortisone 
administration11. Further investigation of possibilities other than stabilization of circulatory dynamics, such as 
post-resuscitation encephalopathy, is necessary to elucidate the mechanism whereby hydrocortisone administra-
tion shortens the duration of hospitalization.
We acknowledge that there are several limitations to this investigation. First, the claims dataset included data with 
no mention of the date of cardiac arrest; these data were missing in 19% of cases. When the analysis was performed 
Hydrocortisone group 
(n = 61)
Non-hydrocortisone 
group (n = 2172) Total (n=2233) p-value
Standardized 
mean difference
Age (years), mean ± SD 51.43 ± 14.17 51.30 ± 13.19 51.29 ± 13.21 0.8353 0.01
Male sex, n (%) 38 (62) 1586 (73) 1624 (73) 0.0641 0.24
OHCA, n (%) 6 (10) 325 (15) 331 (15) 0.3601 0.14
ROSC, n (%) 15 (25) 182 (8) 197 (9) <0.0011 0.57
Comorbidity, n (%)
  Ischaemic heart disease 17 (28) 762 (35) 779 (35) 0.2441 0.15
  Heart failure 18 (30) 797 (37) 815 (36) 0.2501 0.15
  Chronic lung disease 28 (46) 572 (26) 600 (27) <0.0011 0.44
  Hypertension 33 (54) 1269 (58) 1302 (58) 0.4991 0.09
  Diabetes 23 (38) 949 (44) 972 (44) 0.3521 0.12
  Cerebrovascular disease 10 (16) 465 (21) 475 (21) 0.3451 0.12
  Renal disease 13 (21) 297 (14) 310 (14) 0.0891 0.22
  Liver disease 25 (41) 642 (30) 667 (30) 0.0541 0.25
  Adrenal disease 0 (0) 16 (1) 16 (1) 1.0002 0.09
  Hyperlipidaemia 15 (25) 579 (27) 594 (27) 0.7191 0.05
  Cancer 35 (57) 840 (39) 875 (39)  0.0031 0.38
Drugs administered, n (%)
  Vasopressin 5 (8) 13 (1) 18 (1) <0.0012 0.85
  Methylprednisolone 16 (26) 80 (4) 96 (4) <0.0011 1.11
  Dopamine 39 (64) 469 (22) 508 (23) <0.0011 1.01
  Noradrenaline 27 (44) 300 (14) 327 (15) <0.0011 0.86
  Amiodarone 6 (10) 103 (5) 109 (5) 0.1191 0.24
  Nifecarant 2 (3) 28 (1) 30 (1) 0.1972 0.17
  Lidocaine 12 (20) 123 (6) 135 (6) <0.0011 0.59
Adrenaline dose (mg), 
mean ± SD 5.63 ± 12.52 2.26 ± 4.79 2.36 ± 5.18 <0.001
3 0.65
Number of defibrillation 
attempts, mean ± SD 0.49 ± 0.70 0.94 ± 0.55 0.44 ± 0.55 0.800
3 0.10
Tracheal intubation, n (%) 31 (51) 721 (33) 752 (34)  0.0041 0.37
Artificial respiration, n (%) 43 (70) 932 (43) 975 (44) <0.0011 0.56
Hypothermia therapy, n (%) 4 (7) 29 (1) 33 (1) 0.0112 0.43
Table 1. Baseline characteristics of patients in the hydrocortisone and non-hydrocortisone groups. OHCA, 
out-of-hospital cardiac arrest; ROSC, return of spontaneous circulation; SD, standard deviation. 1Chi-square 
test. 2Fisher’s exact test. 3Mann-Whitney test.
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using the data that had the date of cardiac arrest, the rate of survival to discharge tended to be higher in the hydro-
cortisone group, but not significantly so. Second, the claims data do not include several information. For example, 
results such as the Cerebral Performance Category (CPC) score and laboratory test results; hence, we could not eval-
uate the effect of hydrocortisone on neurological outcomes. Also, information on the interval from cardiac arrest to 
initiating advanced life support and the quality of cardiopulmonary resuscitation provided cannot be obtained from 
claims data; there is a possibility that such information may influence the findings. Moreover, we could not obtain 
information regarding the actual indication for hydrocortisone. We are currently conducting multicentre, retrospec-
tive research—we will consider the influence of these factors in that study. Third, there is no detailed description on 
the timing of drug administration in the claims data used in this study. Therefore, it was difficult to examine their use 
separately during CPR and after ROSC, as was done in the study by Mentzelopoulos et al.7,8.
An advantage of the present study is that the study population comprised mostly IHCA patients. To date, 
one randomized controlled trial and one non-randomized prospective study have examined the effects of using 
hydrocortisone monotherapy10,11. One included OHCA patients only, the other comprised mainly OHCA patients. 
On the other hand, combination regimens including vasopressin and epinephrine are used in research involving 
IPTW cohort Matched cohort
Hydrocortisone 
group (n = 61)
Non-
hydrocortisone 
group (n = 2172)
Standardized 
mean 
difference
Hydrocortisone 
group (n = 48)
Non-
hydrocortisone 
group (n = 48)
Standardized 
mean 
difference
Age (years), mean ± SD 51.92 ± 14.23 51.27 ± 13.19 0.05 51.65 ± 14.68 49.65 ± 14.94 0.14
Male sex, n (%) 40 (65) 1586 (73) 0.18 32 (67) 26 (54) 0.26
OHCA, n (%) 13 (22) 326 (15) 0.19 5 (10) 5 (10) <0.01
ROSC, n (%) 5 (8) 195 (9) 0.01 9 (19) 13 (27) 0.20
Comorbidity, n (%)
  Ischaemic heart disease 15 (24) 760 (35) 0.22 14 (29) 14 (29) <0.01
  Heart failure 14 (23) 782 (36) 0.28 15 (31) 16 (33) 0.04
  Chronic lung disease 17 (28) 586 (27) 0.03 20 (42) 24 (50) 0.17
  Hypertension 29 (47) 1260 (58) 0.23 28 (58) 26 (54) 0.08
  Diabetes 20 (32) 956 (44) 0.24 20 (42) 19 (40) 0.04
  Cerebrovascular disease 15 (25) 456 (21) 0.09 9 (19) 7 (15) 0.11
  Renal disease 7 (11) 304 (14) 0.09 12 (25) 9 (19) 0.15
  Liver disease 15 (24) 652 (30) 0.13 21 (44) 12 (25) 0.40
  Adrenal disease 0 (0) 22 (1) 0.09 0 (0) 0 (0) <0.01
  Hyperlipidaemia 16 (27) 586 (27) 0.01 13 (27) 11 (23) 0.10
  Cancer 27 (44) 847 (39) 0.10 28 (58) 26 (54) 0.08
Drugs administered, n (%)
  Vasopressin 1 (1) 22 (1) 0.02 1 (2) 1 (2) <0.01
  Methylprednisolone 2 (4) 109 (5) 0.02 7 (15) 4 (8) 0.20
  Dopamine 23 (38) 500 (23) 0.36 28 (58) 30 (62) 0.08
  Noradrenaline 12 (19) 326 (15) 0.13 17 (35) 18 (38) 0.04
  Amiodarone 5 (9) 109 (5) 0.19 4 (8) 2 (4) 0.17
  Nifecarant 1 (1) 22 (1) 0.08 1 (2) 2 (4) 0.12
  Lidocaine 4 (7) 130 (6) 0.03 10 (20) 3 (6) 0.13
Adrenaline dose (mg), 
mean ± SD 2.82 ± 6.341 2.56 ± 7.14 0.04 4.48 ± 12.62 2.00 ± 2.98 0.27
Number of defibrillation 
attempts, mean ± SD 0.29 ± 0.48 0.44 ± 0.55 0.26 0.40 ± 0.54 0.38 ± 0.49 0.04
Tracheal intubation, n (%) 32 (53) 130 (34) 0.41 24 (50) 16 (33) 0.34
Artificial respiration, n (%) 34 (55) 325 (44) 0.22 33 (69) 28 (58) 0.22
Hypothermia therapy, n (%) 1 (2) 22 (1) 0.03 1 (2) 3 (6) 0.21
Table 2. Weighted and matched baseline characteristics of patients in the hydrocortisone and non-
hydrocortisone groups. OHCA, out-of-hospital cardiac arrest; ROSC, return of spontaneous circulation; SD, 
standard deviation.
Crude IPTW cohort Matched cohort
OR 95% CI p-value OR 95% CI p-value OR 95% CI p-value
Hydrocortisone group 2.2 1.12–3.97 0.015 4.2 1.60–10.98 0.004 2.8 0.88–8.64 0.083
Table 3. Crude and adjusted odds ratios for survival to discharge (hydrocortisone group relative to the non-
hydrocortisone group) IPTW, inverse probability of treatment weighted; OR, odds ratio; CI, confidence interval.
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IHCA patients7,8. Therefore, the effect of steroid monotherapy on the outcomes of IHCA patients is inconclu-
sive. Indeed, in the 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and 
Emergency Cardiovascular Care14, the use of steroids alone in IHCA patients is not recommended. This is because 
in previous studies of IHCA, steroids were used in combination with vasopressin and epinephrine7,8. In present 
study, we adjusted for the use of vasopressin and epinephrine and a propensity score analysis was performed 
so that the effect of hydrocortisone could be evaluated. Based on these points, the novelty of this study is that 
administration of hydrocortisone was associated with a high rate of survival to discharge in a patient population 
comprised mostly of IHCA patients, and the combined use of vasopressin and inotropes was limited.
Because of the unpredictability and urgency of cardiac arrest, it is difficult to assess the effect of medicines on 
the outcomes of cardiac arrest patients. Although the statistical power of this study was not high, in general, anal-
yses using claim data from various medical facilities and patient groups is considered useful because it is easy to 
gather large numbers of cases. This investigation suggests the association between hydrocortisone administration 
and the high rates of survival to discharge. However, further research is necessary to clarify this effect, to evaluate 
differences in effect according to the characteristic of patients, and to determine which patients would derive the 
greatest benefit.
Methods
Data source. The health-insurance claims dataset used in this study, owned by the JMDC, includes claims 
submitted by medical institutions and pharmacies since January 2005 for people aged < 75 years15. In 2015, 
this database included approximately 3 million people, approximating 2% of the Japanese population15. Each 
patient is assigned a unique identifier, allowing patients to be tracked across multiple medical institutions and 
pharmacies. Diagnoses are described using the International Statistical Classification of Diseases and Related 
Health Problems, revision 10 (ICD-10) codes and codes of injuries and diseases. Medications are described using 
the Anatomical Therapeutic Chemical Classification System (ATC) codes and generic names. Medical actions 
are described using Japan-specific medical action codes and the medical fee point’s quick reference table code. 
Because health insurance claims are submitted together once a month, the JMDC’s claims dataset include data 
that do not mention the actual day of an event occurring. There was no description of the exact date of cardiac 
arrest in 51% (n = 1099) of cases. However, since information on the start date of medical treatment for each 
disease can be obtained, we determined the event date using that information. Nevertheless, we were unable to 
determine the exact date of cardiac arrest in 416 cases; for these patients, we used the first day of the month of 
their admission as the event date.
Study population. In this investigation, we used the claims dataset for the period January 2005 to May 
2014. Cardiac arrest was defined as a composite of cardiac arrest, paroxysmal ventricular fibrillation, pulseless 
Figure 1. Probability of survival to hospital discharge, after adjustment using the IPTW method. The 
cumulative rate of survival to discharge adjusted for age of the hydrocortisone group is high in any given point. 
IPTW, inverse probability of treatment weighting.
Hazard ratio 95% CI p-value
Age 1.0 1.01-1.03 0.003
Administration of 
hydrocortisone 4.6 2.18–9.72 <0.001
Table 4. Hazard Ratios for survival to discharge adjusted by IPTW. IPTW, inverse probability of treatment 
weighted; CI, confidence interval.
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ventricular tachycardia, or administration of electrical defibrillation or chest compressions. ICD-10 codes, codes 
of injuries and diseases, Japan-specific medical action codes, and the medical fee point’s quick reference table 
code were used to extract the data of cardiac arrest patients, as shown in Tables 5 and 6. Of the 2,546 patients with 
cardiac arrest, patients who sustained trauma, had no assigned diagnosis, or were < 18 years old were excluded, 
leaving 2,328 patients included for analysis (Fig. 2). These patients were categorized into 2 groups: A hydrocor-
tisone group (patients treated with > 100 mg/day hydrocortisone sodium succinate or hydrocortisone sodium 
phosphate within 1 month after experiencing cardiac arrest) and a non-hydrocortisone group.
Outcome. Patients were considered to have been discharged when “the fee for providing treatment informa-
tion at discharge” was assessed.
Baseline characteristics. Cardiac arrest was defined using either ICD-10 codes (I490: ventricular fibrilla-
tion and flutter, I472: ventricular tachycardia, I469: cardiac arrest, cause unspecified) or the Japan specific medical 
action code (J472: countershock, J046: external cardiac massage). OHCA was defined as case that the standard 
disease name was out-of-hospital cardiac arrest. The definitions of medical history, medical action, and medicine 
are shown in Table S1.
Statistical analysis. To describe the baseline characteristics of patients, continuous variables were summa-
rized as the mean ± standard deviation (SD) or median and interquartile range, and categorical variables were 
summarized using frequencies and percentages. To compare the hydrocortisone and non-hydrocortisone groups, 
Clinical condition ICD-10 code Injury and disease code
Cardiac arrest I469 4275002
Paroxysmal ventricular fibrillation I490 4274001
Ventricular fibrillation I490 4274004
Pulseless ventricular tachycardia I472 8847822
Table 5. Disease-related codes used to identify cardiac arrest patients. ICD-10, International Statistical 
Classification of Diseases and Related Health Problems, revision 10.
Treatment applied Japan-specific medical action code Medical fee point’s quick reference table code
Defibrillation 140051410 or 140010310 J047
Chest compressions 140010210 J046
Table 6. Treatment-related codes used to identify cardiac arrest patients.
Figure 2. Study inclusion diagram.
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the Mann-Whitney U test, chi-square test, or Fisher’s exact test were performed, as appropriate (Table 1). To com-
pare rates of survival to discharge between the two groups, simple logistic regression was performed—crude OR 
and 95% confidence intervals were calculated (Table 3).
A propensity score for administering hydrocortisone was calculated using multiple logistic regression. The 
variables used for the calculation were all factor that listed in Table 2. Propensity scores were used directly as 
inverse weights in estimates of the average effect, known as IPTW. Taking into account differences in patient 
distribution between the two groups, the baseline characteristics of each group were adjusted using the IPTW 
method, which allowed standardization of these characteristics to those of whole patient cohort16 (Table 2). The 
standardized mean difference was used to assess the balance of baseline covariates before and after applying 
IPTW; this difference should be < 0.2517. A weighted logistic regression analysis, using IPTW, was performed 
to estimate the OR comparing the rates of survival to discharge between the two groups (Table 3). Similarly, we 
used the IPTW method to analyze the data of the 1,817 cases whose dates of hydrocortisone administration and 
cardiac arrest were known. As confirmation, we used the propensity score matching method to balance the dis-
tribution of covariates between the two groups: The hydrocortisone group and non-hydrocortisone groups were 
matched 1:1 using nearest neighbor matching. Each matching pair had a propensity score that differed by < 0.001.
A weighted Cox proportional hazards regression analysis, using IPTW, was performed to create survival 
curves and to estimate the hazard ratio and 95% CI of survival to discharge. Because age is a well-known con-
founder that has a marked effect on survival to discharge, this variable was included as a covariate in the Cox 
proportional hazards model. The results are shown in Table 4 and Fig. 1. Patients were censored if they died or 
discontinued their insurance cover.
Analyses were performed using R statistical software version 3.3.2., and statistical significance was defined as 
a p-value < 0.05.
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